Oct. 20 at 5:32 PM
$PACB showing real momentum as its long-read sequencing tech gains traction with new genome project collaborations and expanding partnerships. With giants like
$ILMN and
$TMO leading the biotech landscape, PacBio stands out as the underdog quietly catching up with disruptive precision. If this innovation cycle holds,
$PACB could turn into the most underestimated growth story in genomics .. the calm before a big biotech wave. 🧬